PSC

Mindseeker Awarded $65 Million IDIQ Millennium Challenge Corporation Contract

Retrieved on: 
Monday, January 8, 2024
Consulting, Small Business, Professional Services, Environmental, Social and Governance (ESG), Economic development, Indefinite, Partnership, Trust, PSC, IDIQ, Poverty, MCC, Millennium Challenge Corporation, Sales

Mindseeker, Inc., a professional services firm, announced today that it was awarded a five-year, 65M Indefinite Delivery/Indefinite Quantity (IDIQ) contract with the Millennium Challenge Corporation (MCC).

Key Points: 
  • Mindseeker, Inc., a professional services firm, announced today that it was awarded a five-year, 65M Indefinite Delivery/Indefinite Quantity (IDIQ) contract with the Millennium Challenge Corporation (MCC).
  • The Millennium Challenge Corporation, known for its rigorous selection process and emphasis on promoting sustainable economic growth, has chosen Mindseeker to provide PSC Staffing Support services for the agency.
  • In addition to the tangible benefits of this partnership, Mindseeker recognizes the broader significance of aligning with an organization like the Millennium Challenge Corporation.
  • We look forward to leveraging our skills and resources to deliver outstanding results to the Millennium Challenge Corporation.

Nylabone Earns Accreditation from Pet Sustainability Coalition

Retrieved on: 
Wednesday, January 3, 2024
Sustainability, Environment, Pets, Environmental Issues, Environmental Health, Professional Services, Consumer, Business, Pet, Multimedia, PSC, Friends, PET, Health, Education, Advocate, United, Dog, Love, Climate change, Poverty, Accreditation, Bottled water

Nylabone®, an iconic brand in the Central Garden & Pet portfolio (NASDAQ: CENT) (NASDAQ: CENTA), has been certified as a Pet Sustainability Accredited Business by the Pet Sustainability Coalition (PSC).

Key Points: 
  • Nylabone®, an iconic brand in the Central Garden & Pet portfolio (NASDAQ: CENT) (NASDAQ: CENTA), has been certified as a Pet Sustainability Accredited Business by the Pet Sustainability Coalition (PSC).
  • This accreditation recognizes Nylabone as a sustainably led and measured business that drives positive impact for pets, people, and the planet.
  • The Nylabone commitment to planet-friendly products supports Central Garden & Pet's Impact strategy, which is dedicated to driving sustainability.
  • Founded in 2013, PSC envisions a thriving and collaborative pet industry that creates a positive impact for the communities and environments where pet brands do business.

GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)

Retrieved on: 
Friday, December 8, 2023
Hepatic encephalopathy, Ipsen, AASLD, Cell death, Food, Itch, Priority review, Food and Drug Administration, PSC, IND, ACLF, Marketing, FDA, EMA, MAA, PDUFA, Permeability (electromagnetism), Liver, NDA, Inflammation, Primary sclerosing cholangitis, ALP, Capital market, Hyperammonemia, Patient, NTZ, Fibrosis, PBC, ASK1

Launches in the US and Europe will also make GENFIT eligible for royalty payments.

Key Points: 
  • Launches in the US and Europe will also make GENFIT eligible for royalty payments.
  • Revenues will fund the development of GENFIT’s pipeline, now mainly focused on Acute On-Chronic Liver Failure (ACLF) with 5 differentiated assets.
  • Acceptance of filings in the US and Europe have triggered the first milestone payment for GENFIT.
  • Ipsen also indicated that it is developing elafibranor in Primary Sclerosing Cholangitis (PSC) which could lead to further revenues for GENFIT under the licensing agreement.

Sharc Energy Announces Q3 2023 Financial Results

Retrieved on: 
Wednesday, November 29, 2023
Transfer, GHG, Inflation, Disclosure, HVAC, Heat, University, CFO, Whitney Young, SHARC, Perkins and Will, Cooking, Legislation, False Creek, Adjustment, Carbon, YTD, Senate, WET, State, Water, Energy service company, Prison, Area studies, Exercise, Certification, Dollar, Partnership, PSC, Sale, Urban Land Institute, SHRC, MD, NSF, Energy, Public Service Commission, Growth, Renewable energy

VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- SHARC International Systems Inc. ( CSE: SHRC ) ( FSE: IWIA ) ( OTCQB: INTWF ) ("SHARC Energy" or the “Company”) announces it has filed financial results for the nine months ended September 30, 2023.

Key Points: 
  • VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- SHARC International Systems Inc. ( CSE: SHRC ) ( FSE: IWIA ) ( OTCQB: INTWF ) ("SHARC Energy" or the “Company”) announces it has filed financial results for the nine months ended September 30, 2023.
  • During the three months ended September 30, 2023 (“Q3 2023”), the Company reported revenues of $0.55M, a loss of $0.91M and an Adjusted EBITDA3 loss of $0.63M.
  • SHARC Energy and WET is positioned to gain market share in both the near and long term!”
    Michael Albertson, President of SHARC Energy US, added “I continue to be amazed by the response to the opportunity of WET, which has been overwhelmingly positive within our team’s network of Thermal Energy Network (TEN) experts.
  • For complete financial information for the nine months ended September 30, 2023, please see the Condensed Consolidated Interim Financial Statements and Management Discussion and Analysis (“MD&A”) filed on SEDAR at www.sedar.com .

Leading Neurointerventionalists Say New Insights on TRIAGE-STROKE and RACECAT Affirm Benefits of Direct Transport to CSCs for ELVO Patients

Retrieved on: 
Tuesday, December 19, 2023
CSCS, TCC, Neuroradiology, State, PSC, Risk, Ambient occlusion, Research, EMS, National Association, Health, MD, Triage, ELVO, Stroke, Column, Standard of care, Society, Death, Transport, Patient, Journal, CSC, Life, Pharmaceutical industry

FAIRFAX, Va., Dec. 19, 2023 /PRNewswire/ -- In an Editor's Column published in the Journal of NeuroInterventional Surgery (JNIS), leaders of the Society of NeuroInterventional Surgery (SNIS) conclude that the entire body of research, including evidence from two new prospective trials, clearly confirm that most patients with emergent large vessel occlusions (ELVO) will benefit from triage directly to comprehensive stroke centers (CSCs).

Key Points: 
  • Since the release of this prospective data earlier this year, SNIS leaders say trade media and select hospital systems have issued messaging proclaiming, without qualification, that direct triage programs are ineffective.
  • This has caused concerns about risks to patient care and outcomes in the neurointerventional community.
  • Globally, mechanical thrombectomy is not only considered effective for eligible patients, but firmly established as the standard of care for ELVO patients.
  • These are life and death decisions, and it is our duty as care providers to prioritize patient outcomes over additional profits."

Genel Energy PLC: Trading and operations update

Retrieved on: 
Monday, December 25, 2023
KRG, Genel Energy, Federal government of Iraq, Federal, Malik ibn Tawk, Petroleum industry, Miran, Language, PSC, Ministry, Oil, Bank, Sarta

Genel Energy plc ('Genel' or 'the Company') issues the following trading and operations update in respect of the third quarter and first nine months of 2023.

Key Points: 
  • Genel Energy plc ('Genel' or 'the Company') issues the following trading and operations update in respect of the third quarter and first nine months of 2023.
  • “Despite encouraging comments from senior politicians, the Iraq-Türkiye pipeline remains shut.
  • Good progress has been made in achieving consistency of domestic sales volumes, although pricing continues to be weak.
  • We remain confident that the pipeline exports will resume, and provide access again to international pricing.

Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis

Retrieved on: 
Monday, November 13, 2023
Primary biliary cholangitis, Hepatology, SAN, Myofibroblast, Therapy, PSC, Primary sclerosing cholangitis, PBC, Cirrhosis, AASLD, Toronto Centre, ALK5, Patient, Wound healing, Liver disease, Gene expression, TGF, Liver, Non-alcoholic fatty liver disease, Fibrosis, Trial of the century, ELF, Integrin, Safety, Pharmaceutical industry

These posters were presented at The Liver Meeting® 2023 of the American Association for the Study of Liver Diseases (AASLD).

Key Points: 
  • These posters were presented at The Liver Meeting® 2023 of the American Association for the Study of Liver Diseases (AASLD).
  • “Our presentations at the Liver Meeting feature preclinical and clinical work supportive of bexotegrast’s antifibrotic mechanism of action in liver fibrosis,” said Éric Lefebvre, M.D., Chief Medical Officer of Pliant.
  • An αVβ1-selective integrin inhibitor was evaluated on fibrotic and non-fibrotic human liver tissue to assess the effects on cell populations present in fibrotic human liver tissue.
  • The effects of bexotegrast (PLN-74809), a dual inhibitor of integrins αVβ6 and αVβ1, were assessed on human liver tissue to characterize the response of unique cell populations in fibrotic primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC).

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
ALP, Safety, SAN, Therapy, PSC, Primary sclerosing cholangitis, Data monitoring committee, AASLD, Investment, Biotechnology, Serum, Patient, DSMB, Idiopathic pulmonary fibrosis, Tumor microenvironment, Research, Enrollment, Week, IPF, Pharmacokinetics, Liver, TGF, Alkaline phosphatase, Novartis, Duchenne muscular dystrophy, Biomarker, Cirrhosis, Integrin, ELF, DMD, Fibrosis, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported third quarter 2023 financial results.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported third quarter 2023 financial results.
  • “The third quarter was highlighted by positive interim data from the INTEGRIS-PSC trial of bexotegrast demonstrating a favorable safety profile and encouraging antifibrotic activity in PSC.
  • Positive safety and efficacy data from INTEGRIS-PSC Phase 2a trial in patients with primary sclerosing cholangitis (PSC).
  • These data were selected for an oral late-breaker presentation at next week’s American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2023.

EZCORP Reports Fourth Quarter and Full Year Fiscal 2023 Results

Retrieved on: 
Wednesday, November 15, 2023
Retail, Specialty, Discount, Variety, Other Retail, EBITDA, Acquisition, Security (finance), PSC, Annual report, PIN, Tax, Insurance, Ageing, GAAP, Central Time, EZCORP, Growth, Video game, Pharmaceutical industry, Warehouse, Computer data storage, Uranium mining, Cryptocurrency, PLO

For the fourth quarter, income before taxes decreased to $13.1 million from $13.2 million, and adjusted EBITDA increased 26% to $31.2 million.

Key Points: 
  • For the fourth quarter, income before taxes decreased to $13.1 million from $13.2 million, and adjusted EBITDA increased 26% to $31.2 million.
  • In the fourth quarter, total revenues and gross profit increased 16%, reflecting improved pawn service charge (PSC) revenue, merchandise sales and merchandise sales gross profit.
  • PSC increased 19% in the fourth quarter and 20% for the full year as a result of higher average PLO and yields.
  • EZCORP will host a conference call on Thursday, November 16, 2023, at 8:00 am Central Time to discuss Fourth Quarter Fiscal 2023 results.

Prosimo Launches Cross-Cloud Service Connect, a Single Click to Cross Cloud Networking

Retrieved on: 
Thursday, November 16, 2023
Cloud, Hyperscale computing, SAN, PSC, IP, GCP, Investment, NAT, BigQuery, Control, Azure, S3, Networking hardware, Google Cloud Platform, AI, Platform as a service, AWS, AWS S3, Architecture, Video game, Medical imaging, Mobile phone, Real estate

SAN JOSE, Calif., Nov. 16, 2023 /PRNewswire/ -- Prosimo, a leader in multi-cloud networking solutions, announced the launch of Cross-Cloud Service Connect, a new set of capabilities under its Service Networking architecture. The capability tackles the technical limitations of hyperscaler's PrivateLink & endpoint networking by extending it to multi-region and multi-cloud. The solution works on any underlay - the public cloud backbone, digital infrastructure providers or Google cross-connect, and they all act as a foundational substrate for cross-cloud service connect. The result is one-click simplicity for applications & endpoints to connect natively and securely across clouds.

Key Points: 
  • SAN JOSE, Calif., Nov. 16, 2023 /PRNewswire/ -- Prosimo , a leader in multi-cloud networking solutions, announced the launch of Cross-Cloud Service Connect , a new set of capabilities under its Service Networking architecture.
  • The cloud networking solutions in the market that focus on IP connectivity alone do not understand service endpoints.
  • "Native cloud provider tools such as PrivateLink, at best, solve for a single region of their cloud, not across clouds or regions.
  • Lastly, Cross-Cloud Service Connect removes the complexities associated with networking, access, and security requirements for developers to improve self-service.